Advertisement

Topics

Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 Pipeline Review, H1 2018 [Report Updated: 22052018] Prices from USD $3500

09:35 EDT 14 Aug 2018 | BioPortfolio Reports

Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 Pipeline Review, H1 2018


Summary


Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosinephosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAMindependent.


Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 pipeline Target constitutes close to 28 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 9, 3, 11 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.


Report covers products from therapy areas Immunology, Oncology, Hematological Disorders, Dermatology, Gastrointestinal, Ophthalmology, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Rheumatoid Arthritis, Diffuse Large BCell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Waldenstrom Macroglobulinemia, Autoimmune Disorders, Idiopathic Thrombocytopenic Purpura Immune Thrombocytopenic Purpura, Peripheral TCell Lymphomas PTCL, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Allergic Conjunctivitis, Asthma, Atopic Dermatitis, BCell Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia CLL, Marginal Zone Bcell Lymphoma, NonHodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia CLL, Relapsed Chronic Lymphocytic Leukemia CLL, Ulcerative Colitis, Acquired Autoimmune Hemolytic Anemia, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Allergies, Alzheimer's Disease, Anaphylactic Shock, Arthritis, BCell NonHodgkin Lymphoma, Bladder Cancer, Blood Cancer, Chronic Cutaneous Lupus Erythematosus CCLE / Discoid Lupus Erythematosus DLE, Chronic Urticaria Or Hives, Cutaneous Lupus Erythematosus, Cutaneous TCell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glomerulonephritis, Graft Versus Host Disease GVHD, Head And Neck Cancer Squamous Cell Carcinoma, Inflammation, Inflammatory Bowel Disease, Keratoconjunctivitis sicca Dry Eye, Kidney Transplant Rejection, Lupus Nephritis, Metastatic Breast Cancer, Multiple Myeloma Kahler Disease, Myelofibrosis, NonSmall Cell Lung Cancer, Peritoneal Cancer, PostTransplant Lymphoproliferative Disorder, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sicca Syndrome Sjogren, Solid Tumor, Subacute Cutaneous Lupus Erythematosus SCLE and Systemic Lupus Erythematosus.


The latest report Tyrosine Protein Kinase SYK Pipeline Review, H1 2018, outlays comprehensive information on the Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 targeted therapeutics development with respective active and dormant or discontinued projects.


The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2

The report reviews Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 Pipeline Review, H1 2018 [Report Updated: 22052018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Tyrosine Protein Kinase SYK Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2 Pipeline Review, H1 2018 [Report Updated: 22052018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...